Stock Ratings | UBS raised its price target for Tesla (TSLA) to $442; Citizens lowered its price target for Sharp Link Gaming (SBET) to $30, indicating a potential upside of 463.91%.
Rockwell Medical, Inc. RMTI | 0.00 | |
Lantronix, Inc. LTRX | 0.00 | |
Satellos Bioscience Inc MSLE | 0.00 | |
OS Therapies Incorporated OSTX | 0.00 | |
SharpLink Gaming SBET | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Rockwell Medical ( Rockwell Medical, Inc.(RMTI.US) ), while raising the price target from $2 to $20.
Canaccord Genuity: Maintaining a "buy" rating on Ltrx ( Lantronix, Inc.(LTRX.US) ), while raising the price target from $10.5 to $11.
HC Wainwright & Co.: Maintaining a "buy" rating on Satellos Bioscience ( Satellos Bioscience Inc(MSLE.US) ), while raising the price target from $11 to $18.
Roth Capital: Initial rating for OS Therapies ( OS Therapies Incorporated(OSTX.US) ) stock at "Buy", with a target price of $7.
Citizens: Maintaining its "Outperform Market" rating for SharpLink Gaming ( SharpLink Gaming(SBET.US) ), while lowering its price target from $40 to $30.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Rockwell Medical, Inc.(RMTI.US) | to lift | $20.0 | $5.765 | 246.92% | HC Wainwright & Co. |
| Lantronix, Inc.(LTRX.US) | to lift | $11.0 | $5.7 | 92.98% | Canaccord Genuity |
| Satellos Bioscience Inc(MSLE.US) | to lift | $18.0 | $9.44 | 90.68% | HC Wainwright & Co. |
| Adient plc(ADNT.US) | to lift | $34.0 | $19.49 | 74.45% | UBS |
| Oncology Institute, Inc.(TOI.US) | to lift | $9.0 | $5.85 | 53.85% | BTIG |
| OS Therapies Incorporated(OSTX.US) | Initial classification | $7.0 | $1.72 | 306.98% | Roth Capital |
| SharpLink Gaming(SBET.US) | cut | $30.0 | $5.32 | 463.91% | Citizens |
| Byrna Technologies Inc.(BYRN.US) | cut | $12.0 | $3.94 | 204.57% | B. Riley Securities |
| Ivanhoe Electric Inc.(IE.US) | cut | $20.0 | $9.05 | 120.99% | JP Morgan |
| Coinbase(COIN.US) | cut | $325.0 | $158.44 | 105.12% | Citizens |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
TD Securities: Maintaining a "buy" rating on Applied Materials ( Applied Materials, Inc.(AMAT.US) stock, while raising the price target from $525 to $700.
Truist Securities: Maintaining a "Hold" rating on GitLab GITLAB INC.(GTLB.US) ) stock, while raising the price target from $25 to $30.
Goldman Sachs: Maintaining a "neutral" rating on SoFi Technologies ( SoFi(SOFI.US) , while raising its price target from $17 to $21.
UBS: Maintaining a "neutral" rating on Tesla Tesla Motors, Inc.(TSLA.US) ) stock, while raising its price target from $364 to $442.
First Coverage
Benchmark: A preliminary rating of "buy" for Axos Financial ( Axos Financial, Inc.(AX.US) ) stock, with a target price of $115.
Cantor Fitzgerald: Initial rating for Merlin ( Merlin, Inc.(MRLN.US) ) stock at "overweight", with a price target of $11.
reduction
RBC Capital: Downgraded AeroVironment ( AeroVironment, Inc.(AVAV.US) ) to "Industry Compatibility," with a price target cut from $210 to $180.
Barclays: Maintaining an "underweight" rating on Coinbase Global Coinbase(COIN.US) , while lowering its price target from $107 to $99.
Citigroup: Maintaining a "buy" rating on Netflix Netflix(NFLX.US) ) stock, while lowering its price target from $115 to $100.
Mizuho: Maintaining a "neutral" rating on ExxonMobil Exxonmobil Holdings Corporation(XOM.US) ) stock, while lowering the price target from $175 to $170.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.